Flotyńska Justyna, Uruska Aleksandra, Araszkiewicz Aleksandra, Zozulińska-Ziółkiewicz Dorota
Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Raszeja Hospital, Poznan, Poland.
Endokrynol Pol. 2018;69(6):696-704. doi: 10.5603/EP.a2018.0070.
The fibroblast growth factor 23 (FGF23) and Klotho system play a very important role in the regulation of the human body metabolism. On the one hand, they promote longevity, and on the other hand they promote insulin resistance. Nowadays, accelerated aging in diabetes as the main consequence of chronic complications of the disease is postulated. Signalling pathways induced by insulin, insulin-like growth factor (IGF-1), and their homologues play an important role in controlling the aging process. Because FGF23/Klotho system affects glucose metabolism and gene expression of antioxidant enzymes, changes in its concentration may be a marker of chronic complications of diabetes or a treatment option. Despite huge improvements in the treatment of diabetes, its chronic complications remain an important clinical problem. An interesting issue is the relationship between the concentration of FGF23/Klotho and management of the disease, duration, insulin resistance, and development of complications in type 1 diabetes.
成纤维细胞生长因子23（FGF23）和α-klotho系统在人体新陈代谢的调节中发挥着非常重要的作用。一方面，它们促进长寿，另一方面它们促进胰岛素抵抗。如今，有人推测糖尿病中的加速衰老作为该疾病慢性并发症的主要后果。胰岛素、胰岛素样生长因子（IGF-1）及其同源物诱导的信号通路在控制衰老过程中起着重要作用。由于FGF23/α-klotho系统影响葡萄糖代谢和抗氧化酶的基因表达，其浓度变化可能是糖尿病慢性并发症的标志物或一种治疗选择。尽管糖尿病治疗有了巨大改善，但其慢性并发症仍然是一个重要的临床问题。一个有趣的问题是FGF23/α-klotho浓度与1型糖尿病的疾病管理、病程、胰岛素抵抗和并发症发生之间的关系。
